Clinical Trials Directory

Trials / Unknown

UnknownNCT02739048

Changes of Immunologic Function in Patients of Prostate Cancer Induced After Cryoablation.

Status
Unknown
Phase
Study type
Observational
Enrollment
80 (estimated)
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
Sex
Male
Age
40 Years – 80 Years
Healthy volunteers
Not accepted

Summary

1\. The overall objective of the study: By evaluating the curative effect of CSAP in localized prostate cancer, locally advanced prostate cancer and metastasis advanced prostate cancer, and the change of state in cellular immunity and humoral immunity before and after CSAP. Validate the clinical therapeutic effect of all kinds of prostate cancer, as well as the change of immune status before and after CSAP. 2\. The main content of the study: 1. Included in the samples are patients in hospitals for CSAP. The sample capacity are planned to be 80. The main purpose of the study is to observe the overall survival rate , disease free survival rate, the progress time of the PSA biochemical recurrence as well as the disease progress time. 2. Measure the change of concentration in peripheral blood T lymphocyte subsets (CD3 + T, CD4 + T, CD8 + T, CD4 + / CD8 + T, NK cells) and regulatory T cells before and after cryoablation within 1 month, 3 months and 6 months. 3. Measure the change of concentration in peripheral blood IFN-1, IL-4, IFN-1/IL-4 ratio (Thl/Th2 ratio), and detect the secretion of CD4 + Th tumor-specific IFN-l and the activity of tumor-specific killer CD8 + CTL before and after cryoablation within 2 weeks and 1 month. 4. Before cryoablation, detect the expression and distribution of Follistatin-Like1 (FSTL-1), Besides, verify the connection between the number and activation ratio of tumor local dendritic cells (DC) and the FSTL-1, evaluating the cryoablation effect on the immune response.

Conditions

Timeline

Start date
2015-09-01
Primary completion
2018-09-01
Completion
2018-09-01
First posted
2016-04-14
Last updated
2016-04-21

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02739048. Inclusion in this directory is not an endorsement.